



ASX ANNOUNCEMENT

12 June 2026

Vitrafy Life Sciences Successfully Completes A\$30 Million Institutional Placement

Highlights

- Firm commitments received for a A\$30 million institutional placement (“**Placement**”) at a price of A\$2.60 per share.
- The Offer was strongly supported by new and existing institutional and sophisticated investors following recent announcement of progress on the opportunity in the US blood market.
- A Share Purchase Plan (“**SPP**”) offer to be made to eligible shareholders in Australia and New Zealand to raise up to a further A\$2 million at the same price as the Placement.
- Proceeds to fund the manufacturing of Guardion devices to meet anticipated demand, with additional funds deployed towards the acceleration of US operations and sales and marketing activities.

Overview

Vitrafy Life Sciences Limited (ASX: VFY) (“**Vitrafy**” or “**the Company**”) is pleased to announce it has received firm commitments for its non-underwritten institutional placement to raise A\$30 million (the “**Placement**”). The Placement was strongly supported by new and existing institutional and sophisticated investors.

The Placement comprises the issue of approximately 11,538,462 new fully paid ordinary shares (“**New Shares**”) at a price of A\$2.60 per share (“**Offer Price**”). New Shares issued under the Placement will rank equally with existing Vitrafy shares as at their date of issue.

The Offer Price represents a discount of 31.6% to the last closing price of A\$3.80 per share on 9 June 2026 and an 8.8% discount to the 15-day volume weighted average price (“**VWAP**”) of A\$2.851 up to and including Tuesday 9, June 2026.

The Placement is being conducted under Vitrafy’s available placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A. Accordingly, no shareholder approval is required for the Placement.

Of the 11,538,462 shares being issued under the Placement, 5,153,495 shares are being issued under the Company’s ASX Listing Rule 7.1. capacity and 6,384,967 shares are being issued under the Company’s ASX Listing Rule 7.1.A. capacity.

Managing Director and CEO, Brent Owens, said:

“With recent commercial milestones being achieved in the US blood market, we are more increasingly confident about the growth opportunities for the Company. This capital enables us to scale Guardion manufacturing to meet demand and accelerate the growth in our US operations as we progress towards our commercialisation and medical device registration milestones.”



“We want to thank all investors, new and existing, for their support of the Company as we continue to execute on our vision of improving healthcare outcomes through high-quality cryopreservation outcomes.”

Use of Funds

Proceeds from the capital raising are intended to be applied towards the following:

- Funding the manufacturing of Guardion devices to meet anticipated demand;
- Accelerating the expansion of Vitrafy’s US sales and operations;
- Supporting general working capital; and
- Payment of the costs of the Placement and SPP.

Share Purchase Plan

Vitrafy will also offer eligible shareholders the opportunity to participate in a non-underwritten SPP to raise up to A\$2 million. Under the SPP, shareholders with a registered address in Australia or New Zealand on Vitrafy’s register at 7:00pm AEST on Thursday, 11 June 2026 (the “**Record Date**”) will have the opportunity to apply for up to a maximum of A\$30,000 of new fully paid ordinary shares, free of any brokerage, commission or other transaction costs, irrespective of the size of their holding.

New shares issued under the SPP will be issued at the Offer Price, being A\$2.60 per share, and will rank equally with existing Vitrafy shares as at their date of issue. The SPP will be subject to the eligibility criteria and other terms and conditions set out in the SPP Offer Booklet to be released to the ASX on or about Friday, 19 June 2026.

The SPP is not underwritten and is capped at \$2m. The Company reserves the right (in its absolute discretion) to scale back applications.

Indicative Placement and SPP Timetable

| Event | Date |
|--|-------------------------|
| Institutional Placement | |
| Announcement of Placement results and SPP | Friday, 12 June 2026 |
| Trading halt lifted and shares resume normal trading | Friday, 12 June 2026 |
| Settlement of New Shares issued under the Placement | Wednesday, 17 June 2026 |
| Allotment of New Shares issued under the Placement | Thursday, 18 June 2026 |
| Share Purchase Plan | |
| Record Date for SPP (7:00pm, Sydney time) | Thursday, 11 June 2026 |
| SPP Offer opens and SPP Offer Booklet despatched | Friday, 19 June 2026 |
| SPP Offer closes (5:00pm, Sydney time) | Friday, 3 July 2026 |
| Announcement of SPP results | Wednesday, 8 July 2026 |
| Settlement and allotment of New Shares under the SPP | Thursday, 9 July 2026 |

The above timetable is indicative only. The Company reserves the right to amend any or all of these dates and times, subject to the ASX Listing Rules and the Corporations Act.

For personal use only



Joint Lead Managers

The Company was advised on the institutional placement by the Joint Lead Manager (“JLM”) syndicate of Bell Potter Securities Limited, Jarden Australia Pty Ltd and Morgans Corporate Limited.

ENDS

This announcement is authorised for release by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Tim Sharpe

Vice President of Strategy and Corporate Development

investors@vitrafy.com

About Vitrafy Life Sciences Limited

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardian cryopreservation freezing unit, and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: **VFY**).

For more information visit vitrafy.com

For personal use only